top of page

LATEST NEWS

Approved Marine Drugs

February 2023 

  • All links were checked and are working properly. 

  • Clinical trial numbers were updated accordingly.  

January 2023 

© 2021-2023 Marine Pharmacology

December 2022 

  • All the links have been checked and were working properly, except links addressing compounds in Chinese clinical trials. We are working with Dr. Jinbo Yang's group to update these links.

  • The approved marine-derived pharmaceutical Belantamab Mafoditin-blmf  (Blenrep) withdrawal process was initiated on 11-22-2022, following the request of the FDA. The agency's request was based on the previously announced outcome of the Phase III DREAMM-3 confirmatory trial, which did not meet the requirements of the FDA accelerated approval regulations. (https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/).   

October 2022 

  • All the links have been checked and were working properly.

  • The number of current clinical trials was updated accordingly.

September 2022 

© 2021-2023 Marine Pharmacology
bottom of page